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Background: This study was designed to investigate the effect of glucose 6-phosphate dehydrogenase (G6PD)
deficiency on pro-inflammatory cytokine secretion using a palmitate-induced inflammation HepG2 in vitro model.
The modulation of cellular pro-inflammatory cytokine expression under G6PD deficiency during chronic hepatic
inflammation has never been investigated before.
Methods: The culture medium of untreated and palmitate-treated G6PD-scramble (Sc) and G6PD-knockdown (Gi) HepG2
cells were subjected to cytokine array analysis, followed by validation with ELISA and qRT-PCR of the target cytokine. The
mechanism of altered cytokine secretion in palmitate-treated Sc and Gi HepG2 cells was examined in the presence of
anti-oxidative enzyme (glutathione peroxidase, GPX), anti-inflammatory agent (curcumin), NF-κB inhibitor (BAY11-7085)
and specific SiRNA against NF-κB subunit p65.
Results: Cytokine array analysis indicated that IL-8 is most significantly increased in G6PD-knockdown HepG2 cells. The
up-regulation of IL-8 caused by G6PD deficiency in HepG2 cells was confirmed in other G6PD-deficient cells by qRT-PCR.
The partial reduction of G6PD deficiency-derived IL-8 due to GPX and NF-κB blockers indicated that G6PD deficiency
up-regulates pro-inflammatory cytokine IL-8 through oxidative stress and NF-κB pathway.
Conclusions: G6PD deficiency predisposes cells to enhanced production of pro-inflammatory cytokine IL-8.
Mechanistically, G6PD deficiency up-regulates IL-8 through oxidative stress and NF-κB pathway. The palmitate-induced
inflammation in G6PD-deficient HepG2 cells could serve as an in vitro model to study the role of altered redox
homeostasis in chronic hepatic inflammation.
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Glucose 6-phosphate dehydrogenase (G6PD) catalyzes
the rate-limiting step in the hexose monophosphate
shunt with the concomitant generation of reduced
nicotinamide adenine dinucleotide phosphate (NADPH),
which is involved in cellular reductive biosynthesis and
redox homeostasis [1]. G6PD deficiency, also known as
favism, is one of the most common genetic disorders in* Correspondence: dtychiu@mail.cgu.edu.tw
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unless otherwise stated.the world affecting an estimated four hundred million
people worldwide [2]. G6PD is the only enzyme in eryth-
rocytes to regenerate NADPH and subsequently gluta-
thione (GSH), which protects red cells against oxidative
attacks. G6PD-deficient erythrocytes are particularly sus-
ceptible to hemolysis upon exposure to oxidants such as
fava beans or primaquine. Classically, since G6PD defi-
ciency has been associated with hemolytic crise as a
major clinical manifestation [3], most studies on G6PD
deficiency have been focused on erythrocytes [4]. Re-
cently, an increasing number of studies have shown that
G6PD deficiency not only affects erythrocytes, but also
induces aberrations of cellular functions in nucleated
cells [5-11].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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inflammation and immune response [12]. During inflam-
mation, the production of intracellular reactive oxygen
species (ROS) is involved in triggering inflammatory re-
sponses via the secretion of pro-inflammatory cytokines,
which can directly affect the course of inflammation-
associated diseases [13,14]. Among the pro-inflammatory
cytokines, Interleukin-8 (IL-8) has received much at-
tention owing to its capacity to mediate polymorpho-
nuclear neutrophils (PMN) chemotaxis through CXC
chemokine receptor 1 (CXCR1) and 2 (CXCR2) [15].
Several stimulating factors are known to up-regulate
the expression of IL-8, including lipopolysaccharide
(LPS) [16], phytohemagglutinin (PHA) [17], aggregated
immune complex (IC) [18], tumor necrosis factor
(TNF) [19], Interleukin-1β (IL-1 β) [20] and palmitate
[21-24]. The activation of nuclear factor kappa B (NF-
κB), NF-IL-6 (C/EBP β) or activator protein-1 (AP-1) is
required for the transcription of IL-8 [25-27]. Although
redox status is known to modulate cytokines, the rela-
tionship between G6PD and pro-inflammatory cyto-
kines, such as IL-8, has been overlooked. Further
investigation is warranted for how G6PD modulates
pro-inflammatory cytokines and affects the inflamma-
tory response.
Inflammation is a critical component in different types
of acute and chronic liver disorders, which consequently
progress to hepatitis and fibrosis [28]. In this study, we
have adopted a palmitate-induced inflammation HepG2
in vitro model [29] and performed cytokine array analysis
to investigate the role of G6PD during chronic hepatic in-
flammation. We have shown that G6PD modulates the
secretion of the pro-inflammatory cytokine IL-8 via oxida-
tive stress and NF-κB pathway because the elevated IL-8
due to G6PD deficiency is partially blocked by exogenous
antioxidant and NF-κB inhibitors. These findings suggest
that G6PD may play an important role in the modulation
of chronic hepatic inflammation.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), fetal calf
serum (FCS), streptomycin, and penicillin were pur-
chased from Invitrogen (CA, USA). Hydrogen peroxide
was obtained from Merck (Darmstadt, Germany). BAY11-
7085 (NF-κB inhibitor) was purchased from Calbiochem
(Millipore, MA, USA). Glutathione peroxidase, curcumin
and human SiRNA of scrambled control and p65, were
purchased from Sigma (MO, USA)
Cell culture
Human hepatocarcinoma cell lines HepG2, SK-Hep1 and
the primary human foreskin fibroblast (HFF) were grown
in DMEM supplemented with 10% FCS, antibiotics(100 units/ml penicillin and 100 mg/ml streptomycin)
and 5% CO2 at 37°C. The construction and generation
of the G6PD scramble control (Sc, G6PD normal) and
G6PD shRNA (Gi, G6PD-deficient) HepG2 cells [7,30]
as well as G6PD scramble control (SK-i-Sc, G6PD nor-
mal) and G6PD shRNA (SK-i-Gi, G6PD-deficient) SK-
Hep1 cells [11] were described previously. The isolation
and the characterization of normal primary HFF (HFF3,
G6PD normal) and its G6PD-deficient HFF counterpart
(HFF1, G6PD-deficient) were reported previously [31].
Induction of palmitate overload in HepG2 cells
The induction of palmitate overload in HepG2 cells was
performed according to a published protocol [29]. In
brief, 3×106 HepG2 cells were cultured in petridish for
overnight at 37°C. The culture medium was then re-
placed with fresh medium containing palmitate and the
cells were continued to culture for 24 hr. The palmitate-
containing medium was prepared by diluting 150 mM
palmitate stock solution (dissolved in isopropanol) to
DMEM supplemented with 1% fatty acid free bovine
serum albumin (Sigma) followed by overnight incubation
at 37°C.
Cell viability assay
The HepG2 cell viability was measured based on the
Neutral Red uptake assay described previously [6]. In
brief, 1.2×105 untreated or palmitate-treated Sc and Gi
HepG2 cells were cultured in 24-well plates for over-
night at 37°C. At the end of treatment, cells were incu-
bated with 0.5 ml of 0.033% Neutral Red solution for
2 hr at 37°C followed by fixation with 0.5 ml of 0.1%
CaCl2 and 0.5% formaldehyde for 5 min. Subsequently,
the incorporated dye was solubilized in 0.5 ml of 1%
acetic acid and 50% ethanol solution. The absorbance of
Neutral Red was detected at 540 nm with a reference
wavelength at 690 nm using a SpectraMax 340PC384
microplate reader (Molecular Devices, CA, USA).
ROS measurement and ROS treatment
The ROS level of palmitate-treated Sc and Gi HepG2
cells was analyzed by flow cytometry based on a previ-
ous protocol [6]. In brief, 3×106 HepG2 cells were cul-
tured in petridish for overnight at 37°C. After palmitate
treatment, cells were incubated with 20 μM 2′, 7′-
dichlorodihydrofluoroscein diacetate (DCF-DA) solu-
tion (Molecular Probes, OR, USA) for 30 min at 37°C
followed by Trypsin-EDTA treatment. The trypsinized
cells were then detected for ROS production by a FACS
Calibur flow cytometer (Becton Dickson, CA, USA)
(excitation 490 nm, emission 520 nm). The data was
analyzed by Cell Quest Pro software (Becton Dickson).
For ROS treatment, 3×106 Sc and Gi HepG2 cells
were seeded separately in petridish. After 24 hr, the
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without 0.5 mM H2O2 and continued to culture for
24 hr. After the treatment, the medium of Sc and Gi
HepG2 cells were collected for the determination of
IL-8 secretion.
Gene expression by quantitative real-time PCR
The quantitative real-time PCR (qRT-PCR) was con-
ducted by using SYBR Green PCR Premix reagent
(Yeastern Biotechnology, Taipei, Taiwan) with iQ5 real-
time thermal cycler (Bio-Rad, CA, USA) according to a
previous publication [32]. Primers were designed using
Beacon designer software (Bio-Rad). In brief, HepG2
(3×106 cells), SK-Hep1 (3×106 cells), and primary human
foreskin fibroblasts (5×105 cells) were seeded separately
in petridish and cultured for 3 days until harvesting for
RNA isolation. The RNA was extracted by using TRIzol
reagent (Life Technologies, CA, USA) according to the
instructions provided by the manufacturer. The concen-
tration of RNA was quantified by Nanophotometer
(Implen, Munich, Germany). 1 μg of RNA was reversely
transcribed to cDNA by using SuperScript III Reverse
Transcriptase (Life Technologies) with 0.5 μg of oligo
(dT)18 primer (Bioman Scientific, Taipei, Taiwan). The
qRT-PCR reaction contained 1 μg of cDNA, primers,
and SYBR Green PCR Premix. The thermal cycle pro-
gram was set as followed: 95°C for 10 min, 40 cycles of
95°C for 15 sec and 60°C for 1 min. The gene expression
of IL-8 (forward primer: 5′-CTTTCAGAGACAGCAG
AG-3′; reverse primer: 5′-CTAAGTTCTTTAGCACT
CC-3′) was normalized against threshold cycle (Ct)
values of the housekeeping gene actin (forward pri-
mer: 5′-TCCACCTTCCAGCAGATG-3′; reverse pri-
mer: 5′-GTGTAACGCAACTAAGTCATAG-3′). The
relative index (2-ΔΔCt) was calculated by comparing
the average expression level for control samples with
the index defined as 1.00.
Cytokine profiling
The cytokine profiling of Sc and Gi HepG2 cells with or
without palmitate treatment was determined by using
Human Cytokine Array Panel A, Proteome Profiler™
Array (R&D systems). In brief, 3×106 HepG2 cells were
cultured in petridish for overnight followed by treating
with or without palmitate for 24 hr at 37°C. The culture
medium of each sample was collected and concentrated
with 5 kDa centrifugal filter units (Millipore, MA, USA).
The volume of concentrated medium was adjusted to
1 ml followed by mixing with Cytokine Array Detection
Antibody Cocktail for 1 hr at room temperature. The
concentrated medium/antibody mixture was then incu-
bated with the nitrocellulose membrane, which con-
tains 36 different anti-cytokine antibodies printed in
duplicate, for overnight at 4°C on a rocking shaker(Firstek Scientific, Taiwan). The washed membrane was
incubated with diluted Streptavidin-Horseradish Perox-
idase (HRP) for 30 min at room temperature on a rock-
ing shaker. The membrane was washed and incubated
with chemiluminescent detection reagent for 1 min.
Lastly, the membrane was covered with plastic wrap in
a X-ray film cassette and exposed to X-ray film
(Fujifilm, Japan). The cytokine array data on developed
a X-ray film was quantified by scanning the film on a
transmission-mode scanner. The array image was ana-
lyzed by image analysis software (Image J). The average
signal (pixel density) of duplicate spots representing
each cytokine was obtained by subtracting averaged
background signal on the array. In order to obtain the
relative level of each cytokine between different sam-
ples, the IL-8 protein level of each sample was first
quantified by ELISA. The level of IL-8 was then defined
as a reference to which other cytokines were normal-
ized in each array image. After normalization to IL-8,
comparison of the signal intensity of each cytokine be-
tween array images can be used to determine the rela-
tive level of each cytokine in different samples.
Determination of IL-8 by ELISA
The IL-8 protein level in the culture medium secreted
by Sc and Gi HepG2 cells with or without palmitate
treatment was quantified by the human IL-8 enzyme-
linked immunosorbent assay (ELISA) kit (R&D systems).
In brief, 3×106 HepG2 cells were cultured in petridish for
overnight followed by treating with or without palmitate
for 24 hr at 37°C. The culture medium of each sample was
collected and concentrated with 5 kDa centrifugal filter
units (Millipore). The concentrated medium of each sam-
ple and IL-8 standard (50 μl) were transferred to the wells
containing 100 μl assay diluent in a flat-bottomed 96-well
plate coated with IL-8 antibody and incubated for 2 hr at
room temperature. The plate was aspirated and washed
followed by adding 100 μl IL-8 conjugate (IL-8 antibody
conjugated to HRP) for 1 hr at room temperature. The
plate was then aspirated and washed for four times. The
working solution of Streptavidin-HRP was added subse-
quently and incubated for 30 min at room temperature
followed by aspiration. Lastly, the stabilized chromogen
was added to the plate for 30 min at room temperature in
the dark followed by adding stop solution. The absorbance
of each well was detected at 450 nm with a reference at
490 nm in a microplate reader (Versa MAX, Molecular
Devices). The recombinant human IL-8 protein (R&D
systems) was used for the generation of a standard curve
for IL-8.
Small interfering RNA (SiRNA)
3×105 HepG2 cells were cultured in a 6-well plate for
overnight at 37°C. The culture medium was subsequently
Table 1 The effect of palmitate treatments on the
viability of HepG2 cells
[Palmitate] mM 0 0.2 0.4 0.6
Sc 100% 90% 60% 35%
Gi 100% 91% 50%* 25%*
The viability of palmitate-treated cells was reported in percentage. The data
represent the mean of at least three separate experiments. * indicates a
significant difference (P < 0.05) between Sc and Gi HepG2 cells.
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SiRNA transfection. The cells were transfected with
SiRNA oligonucleotides using 7.5 μl PolyJet In Vitro DNA
Transfection Reagent (SignaGen Laboratories, MD, USA).
Two different SiRNA oligonucleotides were used: (1)
SiRNA against non-targeting scramble control, (2) SiRNA
against human NF-κB subunit p65. Both Sc and Gi HepG2
cells were transfected with SiRNA-control and SiRNA-p65
in different concentrations (50, 100, 150 nM) in a total
volume of 1 ml DMEM per well. After 72 hr incubation,
the culture medium of each well was collected for the de-
termination of IL-8 secretion by ELISA. The cells in each
well were harvested for isolation of RNA and protein for
measuring IL-8 mRNA and p65 level by qRT-PCR and
Western blotting, respectively.
Western blot analysis
The protein lysate isolated from cells was resolved by
SDS-PAGE (TGX Fastcast, Bio-Rad) and electrotrans-
ferred by semi-dry Western blotting (Trans-Blot Turbo
blotting system, Bio-Rad). The immunoblotting was
conducted by using antibody against human p65 (Cell
Signaling technology, MA, USA), actin (Santa Cruz
Biotechnology, TX, USA) according to the protocols
provided by manufacturers.
Statistical analysis
Data were presented as means ± S.D. Student’s t-test
was used to analyze the statistical difference between
G6PD-scramble (G6PD normal) and G6PD-knockdown
(G6PD-deficient) HepG2 cells. Comparisons between
different concentrations or time course of palmitate
treatment were evaluated by one-way analysis of vari-
ance followed by Tukey’s multiple comparison test.
Value of P < 0.05 was considered statistically significant.
Results
Establishment of a G6PD-knockdown HepG2 cell model
with or without palmitate treatment
To investigate the role of G6PD in chronic hepatic inflam-
mation, we adopted a stable G6PD-knockdown HepG2 cell
model [6] undergoing lipid-induced inflammation [29].
Consistent with previous report, the G6PD-knockdown
(Gi) HepG2 cells displayed a significant reduction (10-fold,
P < 0.05) of G6PD catalytic activity (see Additional file 1
for all supplementary materials; Additional file 2: Figure
S1a) as well as protein expression (Additional file 2:
Figure S1b) compared to its G6PD normal counterpart,
G6PD-scramble (Sc) HepG2 cells. Upon palmitate treat-
ment, both Sc and Gi HepG2 cells showed an increase of
lipid deposition as indicated by microscopic examination
with Sudan Red staining (Additional file 3: Figure S2). This
observation was corroborated by flow cytometry analysis
with Nile Red staining (Additional file 4: Figure S3). Toaddress whether palmitate treatment induced cytotoxicity
in HepG2 cell upon G6PD deficiency, the cell viability was
determined in control and palmitate-treated Sc and Gi
HepG2 cells by Neutral Red uptake assay (Table 1). The re-
sult showed that the viability of Sc and Gi HepG2 cells was
reduced by palmitate treatment in a dose-dependent fash-
ion. At 0.4 and 0.6 mM palmitate, there was a significant
difference of viability between Sc and Gi HepG2 cells (P <
0.05). These data demonstrate that in the palmitate-treated
cell model, G6PD deficiency does not affect lipid accumu-
lation, but renders cells more susceptible to cytotoxic effect
at higher palmitate concentrations.
Enhancement of pro-inflammatory cytokine secretion in
G6PD-knockdown HepG2 cells
Since palmitate induces pro-inflammatory cytokine IL-8
secretion in hepatocytes [21], we investigated whether
G6PD deficiency affected pro-inflammatory cytokine se-
cretion in the palmitate-treated cell model by cytokine
array analysis. Among 36 different cytokines tested, sev-
eral cytokines (IL-8, IL-1ra, MIF, sICAM-1, and Serpin
E1) were detected (Additional file 5: Figure S4 and see
the array format in Additional file 6: Table S1). Inter-
estingly, G6PD deficiency enhanced secretion of these
cytokines at basal and palmitate treatment conditions
(Table 2). In particular, the IL-8 secretion showed a 9-
fold increase in palmitate-treated Gi HepG2 cells
compared with untreated Sc HepG2 cells, whereas the
secretion of other high level cytokines showed a 5-fold
increase. Since IL-8 showed a most dramatic increase
in cytokine array, we validated its up-regulation in Gi
HepG2 cells by ELISA (Figure 1a) and qRT-PCR (Figure 2).
The ELISA data confirmed that IL-8 secretion was
significantly increased (P < 0.05) in palmitate-treated Gi
HepG2 cells (Figure 1a) in a palmitate-dependent manner
(Figure 1b). Likewise, the qRT-PCR result also validated
that G6PD deficiency significantly up-regulated IL-8 gene
expression upon palmitate treatment in a palmitate-
dependent manner (Figure 2).
Enhancement of IL-8 expression in other G6PD-deficient
cells
To rule out the up-regulation of IL-8 induced by G6PD
deficiency in HepG2 cell was merely a cell-specific obser-
vation, the IL-8 level of other G6PD-deficient cells (SK-
Table 2 List of differentially expressed cytokines of Sc and Gi HepG2 cells in basal and palmitate-treated conditions
identified by cytokine array
Cytokines Full name Relative level
Basal Palmitate
Sc Gi Sc Gi
IL-8 Interleukin-8 1.00 2.12 3.00 9.18
IL-1ra Interleukin-1 receptor antagonist 1.00 2.57 2.39 5.16
MIF Macrophage migration inhibitory factor 1.00 2.37 3.04 5.88
sICAM-1 Soluble intercellular adhesion molecule-1 1.00 2.22 2.64 5.15
Serpin E1 Serpin peptidase inhibitor, clad E 1.00 2.54 2.60 4.92
In palmitate treatment condition, cells were treated with 0.3 mM palmitate for 24 hr.
The relative intensity of each cytokine was normalized to untreated Sc HepG2 cells as 1.00.
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by qRT-PCR (Figure 3). Significantly elevated IL-8 gene
expression in G6PD-deficient SK-Hep1 and HFF cells was
also observed. These findings suggest that the up-
regulation of IL-8 induced by G6PD deficiency is not a
cell-specific, but a general phenomenon.
Involvement of NF-κB in G6PD deficiency induced IL-8
secretion in HepG2 cells
It has been reported that G6PD activates NF-κB in β-cells
and adipocytes [33,34]. To investigate whether NF-κB
pathway was involved in the enhancement of IL-8 secre-
tion in G6PD-knockdown cells, Sc and Gi HepG2 cells
with or without 0.6 mM palmitate treatment were exposed
to 10 μM NF-κB inhibitor (BAY11-7085) followed by
quantification of IL-8 secretion. As shown in Figure 4a,
IL-8 secretion was significantly reduced by the NF-κB in-
hibitor in Sc HepG2 cells without palmitate treatment
(75% decrease, P < 0.05) compared to that in untreated
control cells. Similarly, the inhibitor reduced the IL-8 se-
cretion in Gi HepG2 cells compared to that in untreated
Gi HepG2 cells without palmitate treatment (64% de-
crease, P < 0.05). In the palmitate-treated cells, the NF-κB
inhibitor significantly reduced IL-8 secretion (80% de-
crease, P < 0.05) in Sc HepG2 cells. Likewise, the NF-κB
inhibitor significantly reduced the palmitate-induced IL-8
secretion in Gi HepG2 cells (72% decrease, P < 0.05) com-
pared with palmitate-treated only Gi HepG2 cells. To fur-
ther investigate the association of G6PD and NF-κB
signaling on IL-8 secretion, a G6PD/ NF-κB(p65) double-
knockdown cell line was established (Figure 4b). Because
the immunoblotting result showed that the protein level
of p65 was diminished markedly by SiRNA against p65 at
150 nM, such condition was used for the measurement of
IL-8 level. The knockdown of NF-κB(p65) in Sc and Gi
HepG2 cells resulted in a significant reduction of IL-8
mRNA (60% decrease, P < 0.05) compared with Sc and Gi
HepG2 cells treated with control SiRNA (Figure 4c). In
addition, Sc and Gi HepG2 cells treated with p65 SiRNA
exhibited diminished IL-8 secretion (40% decrease, P <0.05) compared to Sc and Gi HepG2 cells treated with
control SiRNA (Figure 4d). The blockade of NF-κB due to
selective inhibitor or specific SiRNA against NF-κB con-
firms that the up-regulation of IL-8 caused by G6PD defi-
ciency is linked to NF-κB signaling. Nevertheless, the
finding that the inhibition of NF-κB can not fully suppress
the elevated IL-8 in Gi HepG2 cells suggests that besides
NF-κB pathway there maybe alternative regulatory mech-
anism modulated by G6PD.
Enhancement of IL-8 production by H2O2
G6PD-deficient HepG2 cells are extremely sensitive to
cytotoxic effects induced by oxidants with the concomi-
tant production of oxidative stress [6,7]. To determine
whether the enhanced IL-8 expression in palmitate-
treated Gi HepG2 cells was due to oxidative stress, the
ROS level of Sc and Gi HepG2 cells in control and
palmitate-treated conditions was determined. As shown
in Figure 5, Gi HepG2 cells without palmitate treatment
displayed a 1.4-fold increase of ROS level (P < 0.05) com-
pared with that of control Sc HepG2 cells, while in
palmitate-treated Sc and Gi HepG2 cells there was an
increase in ROS over that in control with a similar ratio
between the two cell types. To examine the effect of oxi-
dative stress on IL-8 secretion, both Sc and Gi HepG2
cells were treated with 0.5 mM H2O2 added exogenously
according to a previous protocol [6] followed by quanti-
fication of IL-8 secretion. As shown in Figure 6, H2O2
treatment significantly enhanced IL-8 secretion in both
Sc and Gi HepG2 cells (5-fold increase, P < 0.05) com-
pared with that in control cells. The dramatic increased
in IL-8 secretion by H2O2, particularly in Gi HepG2
cells, is consistent with the notion that IL-8 secretion in
HepG2 cells is highly sensitive to oxidative stress.
Modulation of IL-8 production by glutathione peroxidase
and curcumin
To corroborate that oxidative stress is a causative agent of
IL-8 up-regulation in palmitate-treated Sc and Gi HepG2
cells, anti-oxidative enzyme glutathione peroxidase (GPX)
Figure 1 The effect of G6PD deficiency on IL-8 secretion in palmitate-treated HepG2 cells. (a) The IL-8 secretion of Sc and Gi HepG2 cells with or without
palmitate treatment (0.6 mM, 24 hr) was measured by ELISA. (b) The IL-8 secretion of Sc and Gi HepG2 cells treated with different concentrations of
palmitate (0.2, 0.3, 0.4 mM) for 24 hr was analyzed by ELISA. These results are representative of at least three separate experiments. *indicates a significant
difference (P< 0.05) between Sc and Gi HepG2 cells. #indicates a significant difference (P < 0.05) between control and palmitate-treated HepG2 cells.
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Figure 7a, exogenous addition of GPX did not affect IL-
8 secretion in Sc and Gi HepG2 cells compared with
untreated control cells (P = 0.18, P = 0.25 respectively).
Despite GPX did not affect palmitate-induced IL-8 in
Sc HepG2 cells (P = 0.35), GPX partially suppressed
palmitate-induced IL-8 (21% decrease, P < 0.05) in Gi
HepG2 cells compared with that in palmitate-treated
Gi HepG2 cells without GPX (Figure 7a). The finding
that there is a significant difference between Sc and Gi
cells in palmitate/GPX co-treatment but not in GPXtreatment alone, indicating that G6PD is required for
lowering pro-inflammatory cytokine secretion caused
by excess ROS due to palmitate stimulation.
On the other hand, curcumin was used as an anti-
inflammatory agent in this study. As shown in Figure 7b,
curcumin treatments (50 and 100 μM) significantly re-
duced the IL-8 level of Sc and Gi HepG2 cells without
palmitate treatment (50 μM: Sc, 71% decrease, Gi, 67% de-
crease; 100 μM: Sc, 70% decrease, Gi, 61% decrease, P <
0.05) compared with control cells without palmitate treat-
ment (Figure 7b). Similarly, the IL-8 level of Sc and Gi
Figure 2 The effect of G6PD deficiency on IL-8 mRNA level in palmitate-treated HepG2 cells. The mRNA level of IL-8 in Sc and Gi HepG2 cells
treated with different concentrations of palmitate (0.2, 0.4, 0.6, 0.8 mM) for 24 hr was analyzed by qRT-PCR. These results are representative of at
least three separate experiments. *indicates a significant difference (P < 0.05) between Sc and Gi HepG2 cells.
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creased by 50 μM curcumin (Sc, 55% decrease, Gi, 67%
decrease, P < 0.05) when compared with that of palmitate-
treated cells without curcumin. Further inhibition of
palmitate-induced IL-8 in both cells occurred when
treated with 100 μM curcumin (Sc, 84% decrease; Gi, 80%
decrease, P < 0.05) compared to that of palmitate-treated
cells without curcumin. These data demonstrate thatFigure 3 The effect of G6PD deficiency on IL-8 mRNA level in cells. The m
SK-Hep1, and HFF) was determined by qRT-PCR. These results are represe
difference (P < 0.05) between G6PD normal and G6PD-deficient cells.curcumin significantly suppresses palmitate-induced IL-8
level in a dose dependent manner in both Sc and Gi
HepG2 cells.
Discussion
As the culprit causing many abnormal cellular functions,
G6PD deficiency is well-known for inducing redox im-
balance [2,3,6,7,10,11,31,35], which exacerbates cellularRNA level of IL-8 in G6PD normal and G6PD-deficient cells (HepG2,
ntative of at least three separate experiments. *indicates a significant
Figure 4 The effect of NF-κB inhibition on IL-8 secretion in HepG2 cells. (a) The effect of NF-κB inhibitor on IL-8 secretion with or without
palmitate treatment. The IL-8 secretion of Sc and Gi HepG2 cells treated with 10 μM NF-κB inhibitor (BAY11-7085) with or without 0.6 mM
palmitate for 24 hr was measured by ELISA. These results are representative of at least three separate experiments. *indicates a significant
difference (P < 0.05) between Sc and Gi HepG2 cells. #indicates a significant difference (P < 0.05) between control and inhibitor (BAY)-treated
HepG2 cells without palmitate. α indicates a significant difference (P < 0.05) between palmitate (PA)-treated cells without inhibitor (BAY) and
palmitate (PA)-inhibitor (BAY) co-treated HepG2 cells. (b) The effect of p65 knockdown in Sc and Gi HepG2 cells on p65 protein level determined by
Western blotting. The blot (cell lysate: 25 μg protein content) was incubated with anti-p65 antibody and subsequently stripped for incubation with
anti-actin antibody as loading control. (c) The effect of p65 knockdown on IL-8 gene expression by qRT-PCR and (d) IL-8 secretion by ELISA. These
results are representative of at least three separate experiments. *indicates a significant difference (P < 0.05) between SiRNA- control and SiRNA- p65.
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Spolarics et al. have shown that ROS detoxifying enzymes,
including G6PD, superoxide dismutase (SOD) and gluta-
thione peroxidase (GPX) are up-regulated in hepatic
endothelial cells of LPS-treated rats [38]. The increased
antioxidant capacity indicates a protective role of G6PD
against oxidative stress during hepatic inflammatory
response [39]. Using G6PD-knockdown HepG2 cells, we
have demonstrated in this study that elevated IL-8 secre-
tion is paralleled with enhanced production of ROS
(Figure 5). Such IL-8 elevation can be further enhanced by
externally applied H2O2 (Figure 6). Our finding of ROS-
induced IL-8 is in accord with previous reports in MKN28
cells [40] and HepG2 cells [41].H2O2 is one of the well-known ROS species that mod-
ulates many signaling pathways [42]. H2O2 activates
tumor necrosis factor-alpha (TNF-α) induced-NF-κB,
whereas the antioxidant N-acetyl-L-cysteine (NAC) sup-
presses TNF-α induced-NF-κB [40]. G6PD can activate
NF-κB in different cell types, including adipocytes in
obesity and β-cells in type-two diabetes [33,34]. Indeed,
NF-κB is involved in the ROS-induced IL-8 transcription
[43]. Additional support to the notion that NF-κB is in-
volved in the up-regulation of IL-8 either by palmitate
treatment or G6PD knockdown in HepG2 cells comes
from our study using the NF-κB inhibitor (BAY11-7085),
which decreases IL-8 secretion at both basal and palmitate
treated conditions (Figure 4a). The fact that knockdown of
Figure 5 The effect of G6PD deficiency on ROS production in HepG2 cells with or without palmitate treatment. The ROS production of
palmitate-treated (0.3 mM, 24 hr) Sc and Gi HepG2 cells was determined by DCF-DA staining and analyzed by flow cytometry. These results are
representative of at least three separate experiments. *indicates a significant difference (P < 0.05) between Sc and Gi HepG2 cells. #indicates a
significant difference (P < 0.05) between control and palmitate-treated HepG2 cells.
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8 level (Figure 4c-d) further implicates a close relationship
between NF-κB signaling and G6PD deficiency-derived
oxidative stress in inflammation.
Antioxidants have been shown to exert the inhibitory ef-
fect on oxidative stress and inflammatory response caused
by NF-κB activation [43-46]. In our current study, the ex-
ogenous addition of ROS scavenging enzyme GPX partiallyFigure 6 The effect of exogenous hydrogen peroxide on IL-8 secretion in
without treatment of 0.5 mM H2O2 for 24 hr was measured by ELISA. The
*indicates a significant difference (P < 0.05) between Sc and Gi HepG2 ce
H2O2-treated HepG2 cells.suppresses the up-regulation of IL-8 in palmitate-treated
G6PD-knockdown HepG2 cells (Figure 7a). The suppres-
sion of IL-8 by GPX is similar to a previous finding that
ROS scavenging agent NAC or dimethylsulfoxide (DMSO)
inhibits IL-8 expression induced by TNF-α or IL-1β [40].
The possible explanation of IL-8 suppression by external
addition of GPX in the culture medium is that GPX can
protect against intracellular H2O2 readily crosses cellHepG2 cells. The IL-8 secretion of Sc and Gi HepG2 cells with or
se results are representative of at least three separate experiments.
lls. #indicates a significant difference (P < 0.05) between control and
Figure 7 The effect of GPX and curcumin on IL-8 secretion in Sc and Gi HepG2 cells with or without palmitate treatment. (a) The IL-8 secretion
of Sc and Gi HepG2 cells co-treated with 2 U/ml glutathione peroxidase (GPX) and 0.6 mM palmitate (PA) for 24 hr was measured by ELISA.
These results are representative of at least three separate experiments. *indicates a significant difference (P < 0.05) between Sc and Gi HepG2
cells. α indicates a significant difference (P < 0.05) between PA without GPX and PA-GPX co-treated HepG2 cells. (b) The IL-8 mRNA of Sc and
Gi HepG2 cells co-treated with 50 or 100 μΜ curcumin (referred to cur50 and cur100, respectively) and 0.6 mM palmitate (PA) for 6 hr was
measured by qRT-PCR. These results are representative of at least three separate experiments. *indicates a significant difference (P < 0.05) between
Sc and Gi HepG2 cells. #indicates a significant difference between control and curcumin-treated HepG2 cells without palmitate. α indicates a
significant difference (P < 0.05) between PA without curcumin and PA-curcumin co-treated HepG2 cells.
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extracellular GPX can dissipate H2O2 out of the cells and
down-regulate H2O2-induced IL-8.
Curcumin (diferuloylmethane) is the pharmacologically
active ingredient found in the spice turmeric (Curcuma
longa) [48]. Recent studies suggest that curcumin exhibits
anti-oxidative [49-51] and anti-inflammatory [52-55] ac-
tivities. In addition, curcumin modulates several transcrip-
tion factors, including AP-1, PPAR-γ, STAT, Nrf-2 andWnt/β-catenin, [56], protein kinases MAP kinase p38 and
ERK [57,58] and inflammatory cytokines TNF-α, IL-6 and
IL-1β [59,60]. In our current study, we show that curcumin
effectively reduces palmitate-induced IL-8 mRNA level
(Figure 7b). Curcumin can ameliorate pro-inflammatory
cytokine production [61], however, it has been reported
that exposure of curcumin significantly induces apoptosis
and cytochrome c release in HepG2 cells as early as 6 hours
after treatment [62]. In our experimental condition, IL-8
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too low to be detected, whereas significantly increased IL-8
mRNA level in palmitate-treated HepG2 cells can be de-
tected at 6 hours. Hence, we determined the effect of cur-
cumin on IL-8 level in palmitate-treated HepG2 cells at
6 hours by qRT-PCR instead of ELISA.
The inactivation of NF-κB is a well-established mechan-
ism of curcumin described in the literature [55,57,63,64]. It
has been shown that curcumin suppresses the phosphoryl-
ation of IκBα (nuclear factor of kappa light polypeptide
gene enhancer in B-cells inhibitor, alpha) through inactiva-
tion of IKK (IkappaB kinase) activity [65]. Moreover, cur-
cumin down-regulates the expression of pro-inflammatory
gene products regulated by NF-κB, including IL-8, through
inhibiting IKK activity in intestinal epithelial cells [66]. A
recent study in sepsis-induced acute lung injury rats shows
that curcumin significantly enhances SOD activity and re-
duces lipid peroxidation in the lung [51]. Furthermore,
curcumin down-regulates inflammatory cytokines TNF-α,
IL-8 and MIF levels in the lung, suggesting a protective role
in counteracting inflammation through down-regulation of
pro-inflammatory cytokines and oxidative stress. Given that
curcumin exerts its inhibitory actions through multiple tar-
gets, it is reasonable to speculate that curcumin may act as
a non-specific anti-inflammatory agent in our study. Such
speculation may justify its superior IL-8 inhibition capacity
compared with GPX and NF-κB inhibitor in this study.
Several reports suggest that G6PD deficiency modu-
lates cytokine response during inflammatory and im-
mune responses. In G6PD mutant endotoxemic mice,
altered cytokines, including elevated blood IL-6 level,
has been documented [67,68]. Clinical studies have indi-
cated that G6PD deficiency correlates with increased in-
cidence of sepsis [69,70]. Moreover, diminished IL-10
and IFN-γ and increased IL-6 are present in African and
Mediterranean forms of G6PD-deficient trauma patients
[71]. Similarly, reduced monocyte IL-10 in G6PD-deficient
trauma patients has been documented [72]. In contrast to
the findings in G6PD-deficient adults, a more recent study
has reported that the toll-like receptor (TLR) agonists-
induced cytokine response in peripheral blood mono-
nuclear cells (PBMCs) isolated from G6PD-deficient
infants, including TNF-α, IL-6 and IL-10, is not differ-
ent from PBMCs of G6PD normal subjects [73]. The
discrepancy between G6PD-deficient adults and infants
may lie in the relative immature innate immune re-
sponse during infancy [74,75]. Additionally, the age of
the subjects may also contribute to the disparity, be-
cause G6PD activity has been suggested to be inversely
proportional to age [76].
Conclusion
We have found that the secretion of pro-inflammatory
cytokine IL-8 is most significantly increased in G6PD-deficient HepG2 cells by utilizing a cytokine array.
Adopting a palmitate-induced inflammation HepG2
cell model, we have found that G6PD deficiency exacer-
bates pro-inflammatory cytokine IL-8 secretion in HepG2
cells. Mechanistically, G6PD deficiency up-regulates
IL-8 through oxidative stress and NF-κB pathway. The
palmitate-induced inflammation in G6PD-deficient HepG2
cells could serve as an in vitro model to study the role of
altered redox homeostasis in chronic hepatic inflammation.Additional files
Additional file 1: Supplementary methods, reference and figure
legends.
Additional file 2: Figure S1. G6PD knockdown reduced G6PD activity
and expression in HepG2 cells. (a) The G6PD activity of G6PD-scramble (Sc)
and G6PD-knockdown (Gi) HepG2 cells were determined by enzymatic
assay. The unit was expressed as U/mg of protein lysate. These results were
representative of at least three separate experiments. *indicates a significant
difference (P<0.05) between Sc and Gi HepG2 cells. (b) G6PD protein
expression of Sc and Gi HepG2 cells were detected by Western blotting, the
amount of G6PD protein was normalized to Actin in the respective sample.
The blot shown was a representative of three separate experiments.
Additional file 3: Figure S2. The morphology of palmitate-treated
HepG2 cells. The morphology of control and palmitate-treated (0.3
mM) Sc and Gi HepG2 cells were visualized by Sudan Red (orange) and
hematoxylin staining (blue).
Additional file 4: Figure S3. The effect of palmitate treatment on lipid
accumulation in HepG2 cells. The lipid levels of control and palmitate-
treated (0.3 mM) Sc and Gi HepG2 cells were quantified by flow cytometry
after Nile Red staining. These results were representative of at least three
separate experiments. # indicates significant difference (P<0.05) between
control and palmitate treatment.
Additional file 5: Figure S4. Cytokine profile of Sc and Gi HepG2 cells
with or without 0.3 mM of palmitate treatment for 24 hr. The result was a
representative of two separate experiments. The normalization of relative
cytokine level was described in the method section. The quantification
result was shown in Table 2.
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